Identifying autoantibody biomarkers for commercial diagnostics and screening applications. Through joint collaborations with top pharmaceutical companies and research institutions, KREX has also been used to identify biologics with therapeutic potentials.

We are actively seeking new collaborations with research and clinical expertise in human cancers, neurodegenerative and autoimmune diseases. For the right partners, Sengenics offers jointly funded collaborations. Please contact us for further details.